AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03918356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical impedance myography
Description: Electrical impedance myography (EIM) is a new electrodiagnostic method of quantitative muscle evaluation. It utilizes concepts of bio impedance, the ability of biological tissue to impede externally applied electrical current.
Study NCT03918356 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: healthy control group
Description: healthy control
Study NCT02075580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychological support (interactive/cognitive strategies)
Description: * cognitive/behavioural intervention (6 times starting from hospital admission, in 90 days; for arm of intervention)~* metacognitive techniques (6 times starting from hospital admission, in 90 days; for arm of intervention)~* psychoeducational intervention (6 times starting from hospital admission; for arm of intervention)~* questionnaires: EORTC questionnaires and a written structured interview (3 times: hospital admission,15 days after surgical intervention, 90 days after intervention; in both arms)
Study NCT01909492 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Patients will provide a serum sample for research.
Study NCT00733681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFC Sigma RP TC3 Revision knee system
Description: Orthopaedic implant system for revision total knee replacement
Study NCT02188654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500mg/day retarded formulation of metformin
Study NCT02188654 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg/day of placebo tablets
Study NCT01764828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Refametinib (BAY86-9766)
Study NCT01764828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT04369950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% lidocaine with 1:200,000 epinephrine and epidural morphine
Description: Epidurals will be dosed with 2% lidocaine with 1:200,000 epinephrine to T4 level in 5ml increments, epidural morphine 3mg will be given after delivery of neonate. T4 level maintained throughout cesarean delivery with additional epidural doses of 2% lidocaine with 1:200,000 epinephrine for both groups. Post-operative orders of scheduled acetaminophen and ibuprofen, and oxycodone as needed will be written.
Study NCT04369950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% 2-chloroprocaine and epidural morphine
Description: Epidurals will be dosed with 3% 2-chloroprocaine to T4 level in 5ml increments, epidural morphine 3mg will be given after delivery of neonate. T4 level maintained throughout cesarean delivery with additional epidural doses of 2% lidocaine with 1:200,000 epinephrine for both groups. This is the critical component to bridge the latency period between the offset of 3% 2-chloroprocaine and the peak action of epidural morphine.Post-operative orders of scheduled acetaminophen and ibuprofen, and oxycodone as needed will be written.
Study NCT01086371 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rhythmic auditory stimulation
Description: Recorded music with embedded beat set 10% above the subject's baseline walking cadence.
Study NCT01086371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmic auditory stimulation
Description: Recorded music with embedded beat set 10% above the subject's baseline walking cadence.
Study NCT01086371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking exercise
Description: Subjects will be walking daily for a total of 20 minutes (may be broken down to smaller time periods.
Study NCT01086371 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking exercise
Description: Subjects will be walking daily for a total of 20 minutes (may be broken down to smaller time periods.
Study NCT06426836 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Amoxicillin-clavulanate
Description: blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care
Study NCT06426836 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Piperacillin-tazobactam
Description: blood sampling in patients receiving piperacillin-tazobactam as part of routine clinical care.
Study NCT06426836 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Meropenem
Description: blood sampling in patients receiving meropenem as part of routine clinical care.
Study NCT06426836 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cefazolin
Description: blood sampling in patients receiving cefazolin as part of routine clinical care.
Study NCT06426836 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vancomycin
Description: blood sampling in patients receiving vancomycin as part of routine clinical care.
Study NCT06426836 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Teicoplanin
Description: blood sampling in patients receiving teicoplanin as part of routine clinical care.
Study NCT06426836 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ciprofloxacin
Description: blood sampling and urine sampling in patients receiving ciprofloxacin as part of routine clinical care.
Study NCT06426836 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Amikacin
Description: blood sampling in patients receiving amikacin as part of routine clinical care.
Study NCT01083589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Oral 400 mg daily
Study NCT01083589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60 mg/m2 over 1 hour intravenous infusion repeated every 21 days.
Study NCT04988009 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical chart
Study NCT04988009 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study NCT01891474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: U-health care
Description: voice inception technique based U-healthcare service
Study NCT04302545 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystoinflation
Description: Bladder retrofill with 300cc saline to distend the bladder to recognize bladder outline
Study NCT01691040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-H94
Description: intravenous injection
Study NCT01691040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo solution
Description: intravenous injection
Study NCT03424460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haemostasis tests
Description: Venipuncture of 30 milliliters of blood. The following tests will be performed: thromboelastography (TEG®), standard tests of coagulation, genetic thrombophilia, lupus anticoagulant, fibrinolysis markers (Alpha-2-antiplasmin, amidolytic activity, plasmin anti-plasmin complexes, Plasminogen Activator Inhibitor-1 (PAI-1) antigen, plasminogen amydolytic activity), and a global test of fibrinolytic activity.
Study NCT03424460 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Haemostasis tests
Description: Venipuncture of 30 milliliters of blood. The following tests will be performed: thromboelastography (TEG®), standard tests of coagulation, genetic thrombophilia, lupus anticoagulant, fibrinolysis markers (Alpha-2-antiplasmin, amidolytic activity, plasmin anti-plasmin complexes, Plasminogen Activator Inhibitor-1 (PAI-1) antigen, plasminogen amydolytic activity), and a global test of fibrinolytic activity.
Study NCT03424460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monocytes and megacaryocytes culture and RNA extraction
Description: Venipuncture of 60 milliliters of blood. Monocytes and megacaryocytes culture. RNA extraction from monocytes and megacaryocytes.
Study NCT03424460 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Monocytes and megacaryocytes culture and RNA extraction
Description: Venipuncture of 60 milliliters of blood. Monocytes and megacaryocytes culture. RNA extraction from monocytes and megacaryocytes.
Study NCT03424460 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RNA extraction
Description: RNA extraction from liver tissue
Study NCT03424460 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: RNA extraction
Description: RNA extraction from liver tissue
Study NCT03922178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressure/Volume Combination Catheter
Description: Hemodynamic data routinely collected and data collected by means of the placement of a Pressure/Volume Combination Catheter (Pressure/Volume Combination Catheter,Leycom,The Netherlands) will be collected simultaneously. The catheter will be placed and held in place as long as the patient is in a position to be assisted by extracorporeal circulation. This means that the placement of the catheter will follow the heparinization of the patient and the placement of the cannulas necessary for the realization of extracorporal circulation. It will be removed from the left ventricular cavity before removal of extra-corporal cannulas.
Study NCT03922178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography
Description: A complete transthoracic echocardiography will be performed the day before the surgical procedure, as per standard of care. It will establish the presence of the inclusion and exclusion criteria and evaluate the contractile function of the left ventricle. This will be done using a Philips IE33 echocardiograph (Koninklijke Philips Electronics N.V., Netherlands).
Study NCT03922178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiogram
Description: A transesophageal echocardiogram will be performed during the cardiac surgery, as per standard of care, using an Acuson Sequoia system (Siemens AG, Germany). It will facilitate the placement of the pressure/volume combination catheter and collect echographic data.
Study NCT03860363 — intervention group
Intervention type: DEVICE
Intervention: Blood drainage post cardiac surgery
Description: Blood drainage post cardiac surgery with Thoraguard Surgical Drainage System.
Study NCT03696901 — intervention group
Intervention type: DRUG
Intervention: Xydalba
Description: Information will be recorded about Xydalba administration (e.g. dose(s), number of infusions, length of infusions, dates or schedule of administration, sites of administration \[e.g. hospital, ICU\]), and reason for discontinuation, including response to treatment to assess whether the patient was clinically improving when Xydalba was discontinued
Study NCT01636349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: soccer exercise or continued daily lifestyle
Description: Recreational soccer or continued unchanged lifestyle
Study NCT01209221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - MAD
Description: Once or twice daily doses of matching placebo to RO5271983 for 14 days
Study NCT04012788 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo powder
Study NCT01209221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - SAD
Description: Single dose of matching placebo to RO5271983 for up to 3 periods
Study NCT01209221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5271983 - MAD
Description: Once or twice daily doses of RO5271983 for 14 days
Study NCT01209221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5271983 - SAD
Description: Single dose of RO5271983 at each period (for up to 3 periods)
Study NCT03402009 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Apps
Description: Apps and weblinks to coach self-guided meditation.
Study NCT03402009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Apps
Description: Apps and weblinks to coach self-guided meditation.
Study NCT03402009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EEG neurofeedback
Description: Device provides feedback based on EEG readings.
Study NCT02313025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: speech sound intervention
Description: An intervention that stimulates speech sound perception and production in four-year-olds.~Each day at preschool the children receive a 15 to 20 minutes intervention, for 12 weeks
Study NCT02313025 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: World-project
Description: An intervention that stimulates vocabulary development in four-year-olds. Each day at preschool the children receive a 120 minutes intervention, for 10 weeks
Study NCT02417051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disaster Worker Resiliency Training
Description: The Disaster Worker Resilience Training (DWRT) Program is a 4 hour program which consists of a participant training manual, an instructor-training manual, and a digital presentation. It uses adult training techniques that emphasize active participation in individual and group experiential learning activities. The curriculum is organized into a preface and four chapters, each with action oriented learning objectives. Overall program objectives include a demonstrate an ability to: 1) Recognize signs and symptoms of disaster work-related stress, 2) Obtain support through employer and community resources, and 3) Build resilience by using stress reduction and coping strategies.
Study NCT03265249 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BRIDGE device
Description: an externally placed, FDA-cleared device that delivers percutaneous electrical stimulation with alternating frequencies to branches of cranial nerves (V, VII, IX, and X) through the external ear via a field effect
Study NCT04623918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron-biofortified rice
Description: Iron-biofortified rice (IR68144-2B-2-2-3)
Study NCT04623918 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control rice
Description: Control rice (C4), identical in appearance
Study NCT04309656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: 1. Treatment A (reference) = 200 mg given as a single 200 mg tablet (using the immediate release formulation), orally administered.~2. Treatment B (test) = 200 mg given as four 50-mg tablets (using the dispersible pediatric formulation), orally administered.~3. Treatment C (test) = single 50-mg dispersible tablet, orally administered.~4. Treatment D (test) = single 10-mg dispersible tablet, orally administered.
Study NCT00935870 — intervention group
Intervention type: DEVICE
Intervention: Bioactive glass and/or autogenous bone
Description: No intervention in the current study (10-year follow-up study)
Study NCT01277523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium high dose
Description: 2 actuations once daily
Study NCT01909492 — intervention group
Intervention type: PROCEDURE
Intervention: Lumbar Puncture
Description: Patients will have a lumbar puncture to obtain CSF.
Study NCT03431246 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil and Gardasil-9
Description: All subjects will receive one dose of Gardasil-9. Blodd samples for serological testing will be collected just before and one month post Gardasil-9 administration.
Study NCT01277523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 actuations once daily
Study NCT01598831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ART-123
Description: Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
Study NCT01598831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days.
Study NCT05151952 — intervention group
Intervention type: RADIATION
Intervention: Other: Registry
Description: Registry of cancer patients who receive proton radiation therapy.
Study NCT02837874 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Isoperistaltic
Description: Same direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the distal part of remnant stomach
Study NCT02837874 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antiperistaltic
Description: Reverse direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the proximal part of remnant stomach
Study NCT02089165 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill oil
Description: Krill oil from Antarctic krill, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration
Study NCT02089165 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill meal
Description: Krill meal, granular meal from Antarctic krill, per oral, targeted daily n-3 PUFA dose of 1 700 mg, single administration
Study NCT02089165 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil
Description: Fish oil, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration
Study NCT03497975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine ER Tablets
Description: Active Nalbuphine ER Tablets
Study NCT03497975 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo Tablets
Description: Matching Tablets with no active substance
Study NCT03497975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine ER Tablets
Description: Open Label Extension
Study NCT03000920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS before invitation
Description: A couple of days before the invitation letter, an SMS will be sent to announce the arrival of the invitation letter to the mammogram
Study NCT03000920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS Reminder 1
Description: If it is necessary for the women to have a reminder 1, the usual mail will be replaced by an SMS.
Study NCT00461552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leptin
Description: weight based, sub-cutaneous injection, twice daily
Study NCT00461552 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: weight based, sub-cutaneous injection, twice daily
Study NCT03811782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single-task Training
Description: In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Single-task Training instructions (20 minutes) and cool down (5 minutes).
Study NCT03811782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-task Training
Description: In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Dual-task Training instructions (20 minutes) and cool down (5 minutes).
Study NCT03811782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Analogy Training
Description: In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Analogy Training instructions (20 minutes) and cool down (5 minutes).
Study NCT03284931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217 high dose
Description: high dose
Study NCT02756494 — intervention group
Intervention type: BIOLOGICAL
Intervention: Ischemic Stroke
Description: Ischemic Stroke in Chinese Young Adults
Study NCT03284931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT03284931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217 low dose
Description: low dose
Study NCT01593566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% Bupivacaine
Description: Femoral nerve block using 0.25% versus 0.5% bupivacaine
Study NCT01277523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium low dose
Description: 2 actuations once daily
Study NCT01593566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% Bupivacaine
Description: Femoral nerve block using 0.25% versus 0.5% bupivacaine for analgesia after ACL reconstruction
Study NCT00086060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise regimen
Description: Aerobic Exercise is a self-management technique that increases personal control over pain by enhancing physical fitness. Patients will be encouraged to choose activities best suited to their tastes and current lifestyle, incorporating lifestyle physical activities (climbing stairs, household chores, etc) and more traditional exercise activities (walking, cycling, etc.). Subjects will use ratings of perceived exertion (RPE) to guide their effort. The intervention will consist of two-hours of face-to-face contact followed by weekly telephone contact for 8 weeks. Face-to-face contract will include receiving a standardized instruction manual for exercise, a demonstration on how to perform relaxation, and tailoring homework assignments to be monitored on the weekly phone call.